CLINICAL TRIAL / NCT05109442
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
- Interventional
- Recruiting
- NCT05109442
Contact Information
A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination With Atezolizumab in Patients With Selected Advanced/Metastatic EGFR-expressing Cancers
AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
There will be 2 parts in this study: a dose escalation phase (phase 1) and an expansion phase
(phase 2a). Patients will qualify to receive the investigational drugs (AFM24 + atezolizumab)
in the dose escalation phase or the expansion phase only if they are deemed eligible
following the safety lead-in phase. Seven days before the planned first combination
treatment, patients will receive a single dose of AFM24 and will be observed for any adverse
events for 1 week.
The aim of the dose escalation phase is to determine the maximum tolerated dose
(MTD)/recommended phase 2 dose (RP2D) of AFM24 in combination with atezolizumab.
The dose escalation phase will be followed by the expansion phase once the MTD/RP2D of AFM24
in combination with atezolizumab has been determined. The expansion phase of the study is
intended to collect preliminary evidence of efficacy and to further confirm the safety of
AFM24 in combination with atezolizumab.
The tumor types planned to be studied in the AFM24/atezolizumab combination study will be:
- Non-small cell lung cancer (EGFR-WT), with disease progression after chemotherapy and
PD1/PD-L1 targeted therapy
- Gastric/GEJ cancer if intolerant to or with disease progression after standard
platinum-based chemotherapy
- Pancreatic/hepatocellular/biliary tract cancer with disease progression after standard
of care (SOC) therapy or if there is no appropriate SOC available for their condition
- Advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation with
disease progression on or after received ≥1 prior lines of treatment for advanced
disease, including a Tyrosine-Kinase Inhibitor (TKI) for EGFR mutations
Gender
All
Age Group
18 Years and up
Accepting Healthy Volunteers
No
Inclusion Criteria:
- Histologically or cytologically confirmed advanced or metastatic EGFR-positive
selected cancer types (except for NSCLC)
- Advanced or metastatic NSCLC, EGFR WT: disease has progressed after ≥ 1 prior lines of
therapy which must have included a platinum-based doublet in combination with
PD1/PD-L1 antibody or must have received an anti-PD1/PD-L1 antibody prior to or after
a platinum-based doublet
- Advanced, unresectable, or metastatic gastric/GEJ adenocarinoma: after ≥ 1 prior
chemotherapy regimen including a platinum and fluoropyrimidine doublet
- Advanced or metastatic HCC (BCLC C or B not amenable or refractory to locoregional
therapy), hepatobiliary-, or pancreatic adenocarcinoma: after ≥1 prior line of an
approved SOC therapy for the respective disease type or to whom the available SOC is
not appropriate in the opinion of the investigator
- Advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and
whose disease has progressed on or after having received ≥ prior TKI approved for EGFR
mutated NSCLC. Subjects trated with a 1st or 2nd generation TKI in 1st line who
developed a documented T790M mutation must have received a TKI targeting this mutation
such as Osimertinib or Lazertinib to be eligible. Subjects must have documentation of
EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor
or circulation free tumor DNA. The patients should have received a 2nd line of
treatment if approved and available or may be enrolled in the study if in the opinion
of the investigator it is in the patient's best interest,or the SOC is not
appropriate.
- Adequate organ function
- Phase 1: Evaluable or measurable disease per RECIST v1.1
- Phase 2a: Measurable disease per RECIST v1.1
Exclusion Criteria:
- Treatment with systemic anticancer therapy including investigational agent within 4
weeks of the first dose of study drug, 6 weeks for mitomycin C or nitrosoureas, 2
weeks (or 5 half-lives whichever is longer) for using fluorouracil or small molecule
targeted drugs, 2 weeks for using traditional Chinese medicine with anti-tumor
indication.
- Radiation therapy within 2 weeks before 1st dose of study drug or unresolved toxicity
from previous radiotherapy
- History of any other malignancy known to be active, with the exception of completely
removed in situ cervical intra-epithelial neoplasia, non-melanoma skin cancer, DCIS,
early stage prostate cancer that has been adequately treated, and other cancers from
which the patient has been disease free for 3 years or longer
- Currently active in any other clinical study, or administration of other
investigational agent
- Solid Tumors